Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $14.5
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14 to $14.5.
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14 to $14.5.